Do we need to rethink the diagnoses melanoma in situ and severely dysplastic naevus?

Br J Dermatol. 2022 Jun;186(6):1030-1032. doi: 10.1111/bjd.21010. Epub 2022 Apr 7.

Caitlin R Semsarian¹, Tara Ma¹, Brooke Nickel¹, Richard A Scolyer^{2

3

4}, Peter M Ferguson^{2

3

4}, H Peter Soyer^{5

6}, Lisa Parker^{7

8}, Alexandra Barratt¹, John F Thompson^{2

3

9}, Katy J L Bell¹

¹ Sydney School of Public Health, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
² Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.
³ Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
⁴ Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital & NSW Health Pathology, Camperdown, NSW, Australia.
⁵ The University of Queensland Diamantina Institute, The University of Queensland, Dermatology Research Centre, QLD, Woolloongabba, Australia.
⁶ Dermatology Department, Princess Alexandra Hospital, QLD, Woolloongabba, Australia.
⁷ Sydney School of Pharmacy, Charles Perkins Centre, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
⁸ Department of Radiation Oncology, Royal North Shore Hospital, Sydney, NSW, Australia.
⁹ Department of Melanoma and Surgical Oncology, Royal Prince Alfred Hospital, Camperdown, NSW, Australia.

No abstract available

MeSH terms